(Q34510671)

2 August 2017

1 reference

title

Olanzapine-induced agranulocytosis: a case report and review of the literature (English)

1 reference

2 August 2017

1 reference

Carles Tolosa-Vilella

1

1 reference

2 August 2017

Ada Ruiz-Ripoll

2

1 reference

2 August 2017

Begoña Mari-Alfonso

3

1 reference

2 August 2017

Elsa Naval-Sendra

4

1 reference

2 August 2017

publication date

1 February 2002

1 reference

Progress in Neuro-Psychopharmacology & Biological Psychiatry

2 August 2017

published in

1 reference

2 August 2017

volume

26

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

411-414

1 reference

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Olanzapine-induced neutropenia after clozapine-induced neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Prolongation of clozapine-induced granulocytopenia associated with olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Olanzapine-induced neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Drugs that induce neutropenia/agranulocytosis may target specific components of the stromal cell extracellular matrix

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Reversible leucopenia related to olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Olanzapine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Olanzapine: safe during clozapine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Treatment of severe clozapine-induced neutropenia with granulocyte colony-stimulating factor (G-CSF). Remission despite continuous treatment with clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Two cases of olanzapine-induced reversible neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Evidence that Lithium Induces Human Granulocyte Proliferation: Elevated Serum Vitamin B12Binding Capacity in Vivo and Granulocyte Colony Proliferation in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-5846%2801%2900258-5

7 January 2021

10.1016/S0278-5846(01)00258-5

Identifiers

DOI

1 reference

2 August 2017

1 reference